Literature DB >> 17524871

The association between cytomegalovirus infection and atherosclerotic events in renal transplant recipients.

F N Ozdemir1, A Akgul, A Altunoglu, A Bilgic, Z Arat, M Haberal.   

Abstract

Cytomegalovirus (CMV) infection is a risk factor for arteriosclerosis in renal transplant recipients. We sought to investigate the effects of CMV infection on atherosclerotic events (AE) in renal transplant recipients. This retrospective analysis included 200 patients: 52 women and 148 men of overall mean age of 36.18 +/- 10.23 years who were transplanted at our center between 1998 and 2001. We analyzed demographic features, dialysis duration, diabetes, blood pressure level, body mass index (BMI), medications, and lipid parameters. CMV infection was diagnosed in 23.5% of patients in the first 2 years after transplantation; these patients were followed for 4 years. All patients had been assessed for AE, including previous myocardial infarction, angina, revascularization procedures, intermittent claudication, stroke, or transient ischemic attack. AE occurred in 13% during the follow-up period. CMV infection was more frequent among these patients compared to those without AE, namely 42.3% versus 20.6%, respectively. Although the gender, dialysis duration, serum cholesterol level, presence of acute rejection, and BMI were not associated with AE, age, hypertension, and CMV infection did show a relation. A multivariate analysis by logistic regression revealed mean age and CMV infection to be independent risk factors for AE: odds ratio (OR)=5.6, 95% confidence interval (CI)=1.3 to 24.6 (P=0.02) and OR=4, 95% CI = 1.3 to 12.3 (P=.01). This study suggested that the presence of CMV infection may be a triggering factor for AE in renal transplant recipients.

Entities:  

Mesh:

Year:  2007        PMID: 17524871     DOI: 10.1016/j.transproceed.2007.02.026

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  7 in total

Review 1.  Infection and Stroke: an Update on Recent Progress.

Authors:  Eliza C Miller; Mitchell S V Elkind
Journal:  Curr Neurol Neurosci Rep       Date:  2016-01       Impact factor: 5.081

2.  The Development of Therapeutics for the Treatment and Prevention of CMV Disease in the Transplant Population: A Regulatory Perspective.

Authors:  Aimee C Hodowanec; Andreas Pikis; Mary E Singer
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

Review 3.  New developments in the management of cytomegalovirus infection after solid organ transplantation.

Authors:  Albert J Eid; Raymund R Razonable
Journal:  Drugs       Date:  2010-05-28       Impact factor: 9.546

4.  Update on cytomegalovirus infections of the gastrointestinal system in solid organ transplant recipients.

Authors:  Tracy L Lemonovich; Richard R Watkins
Journal:  Curr Infect Dis Rep       Date:  2012-02       Impact factor: 3.725

5.  Infectious burden and risk of stroke: the northern Manhattan study.

Authors:  Mitchell S V Elkind; Pankajavalli Ramakrishnan; Yeseon P Moon; Bernadette Boden-Albala; Khin M Liu; Steve L Spitalnik; Tanja Rundek; Ralph L Sacco; Myunghee C Paik
Journal:  Arch Neurol       Date:  2009-11-09

Review 6.  Infectious and coronary artery disease.

Authors:  Mohammad Saeid Rezaee-Zavareh; Mohammad Tohidi; Amin Sabouri; Mahdi Ramezani-Binabaj; Mohsen Sadeghi-Ghahrodi; Behzad Einollahi
Journal:  ARYA Atheroscler       Date:  2016-01

7.  Early renal function trajectories, cytomegalovirus serostatus and long-term graft outcomes in kidney transplant recipients.

Authors:  Jonathan P Law; Richard Borrows; David McNulty; Adnan Sharif; Charles J Ferro
Journal:  BMC Nephrol       Date:  2021-03-20       Impact factor: 2.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.